Zoetis (NYSE:ZTS) Given New $225.00 Price Target at HSBC

Zoetis (NYSE:ZTS) had its target price lowered by HSBC from $230.00 to $225.00 in a research note published on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the stock.

ZTS has been the subject of a number of other reports. Piper Sandler reaffirmed an overweight rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. The Goldman Sachs Group cut their price objective on shares of Zoetis from $223.00 to $196.00 and set a buy rating for the company in a report on Monday. StockNews.com lowered shares of Zoetis from a strong-buy rating to a buy rating in a report on Tuesday, February 20th. Barclays cut their target price on shares of Zoetis from $260.00 to $230.00 and set an overweight rating for the company in a report on Tuesday, April 23rd. Finally, Stifel Nicolaus cut their target price on shares of Zoetis from $195.00 to $180.00 and set a buy rating for the company in a report on Tuesday, April 30th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Zoetis presently has a consensus rating of Buy and an average target price of $211.75.

Zoetis Stock Performance

Shares of NYSE:ZTS traded up $1.50 during trading on Wednesday, hitting $166.42. The company’s stock had a trading volume of 727,321 shares, compared to its average volume of 3,167,603. The company has a 50-day moving average of $167.64 and a 200-day moving average of $178.93. Zoetis has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. The firm has a market cap of $75.94 billion, a price-to-earnings ratio of 32.13, a P/E/G ratio of 2.57 and a beta of 0.86.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. During the same quarter last year, the business earned $1.31 EPS. The firm’s revenue was up 9.5% compared to the same quarter last year. On average, sell-side analysts expect that Zoetis will post 5.77 earnings per share for the current year.

Insider Activity

In other news, EVP Roxanne Lagano sold 363 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the sale, the executive vice president now directly owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders sold 2,209 shares of company stock valued at $371,293. 0.16% of the stock is currently owned by company insiders.

Institutional Trading of Zoetis

Hedge funds have recently added to or reduced their stakes in the business. Blue Bell Private Wealth Management LLC lifted its position in shares of Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after buying an additional 89 shares during the last quarter. Independence Bank of Kentucky lifted its position in shares of Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after buying an additional 130 shares during the last quarter. Private Wealth Management Group LLC purchased a new stake in shares of Zoetis during the fourth quarter valued at about $33,000. Webster Bank N. A. lifted its position in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the last quarter. Finally, Ramirez Asset Management Inc. purchased a new stake in shares of Zoetis during the third quarter valued at about $35,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.